How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,785 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases. (Abstract)

CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases. Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma. Early-stage MF patches or plaques often resemble inflammatory skin disorders (ISDs), including psoriasis and atopic dermatitis. Cell adhesion molecule 1 gene (CADM1), which was initially identified as a tumor suppressor gene in human non-small cell lung cancer, has been reported as a diagnostic marker for adult T-cell leukemia

2018 Journal of American Academy of Dermatology

102. PUVA and interferon-α2b combined therapy for patients with mycosis fungoides at different stages of the disease: a seven-year retrospective study in Russia. (Abstract)

PUVA and interferon-α2b combined therapy for patients with mycosis fungoides at different stages of the disease: a seven-year retrospective study in Russia. 30102807 2019 02 12 1468-3083 33 2 2019 Feb Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol PUVA and interferon α2b combined therapy for patients with mycosis fungoides at different stages of the disease: a seven-year retrospective study in Russia. e72-e74 10.1111/jdv.15212 Olisova O Y OY

2018 Journal of the European Academy of Dermatology and Venereology

103. Retinoic Acid Receptor Agonist as Monotherapy for Early-Stage Mycosis Fungoides: Does it Work? (Abstract)

Retinoic Acid Receptor Agonist as Monotherapy for Early-Stage Mycosis Fungoides: Does it Work? Retinoids exert their biologic effects by binding to intracellular retinoic-acid receptors (RARs) and/or retinoid X receptors (RXRs). Early-stage mycosis fungoides (MF) has been effectively treated with bexarotene, an RXR-agonist, with overall response (OR) rates 54-67% and complete response (CR) rates 7-27%. Data on RAR-agonist monotherapy are limited.To analyze the effectiveness of RAR-agonist

2018 Journal of Dermatological Treatment

104. Dermoscopic patterns of early-stage mycosis fungoides in a Chinese population. (Abstract)

Dermoscopic patterns of early-stage mycosis fungoides in a Chinese population. Early-stage mycosis fungoides (eMF) is a clinical diagnostic challenge because it can mimic inflammatory diseases. Dermoscopy has been reported to be useful in evaluation of eMF in Caucasian patients; however, dermoscopic features of eMF in the Chinese population are lacking.To determine the validity of dermoscopy in the diagnosis and differential diagnosis of eMF in a Chinese population.This was a retrospective

2018 Clinical & Experimental Dermatology

105. Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides

Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Ultra (...) Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03398161 Recruitment Status : Recruiting First Posted : January 12, 2018 Last Update Posted : August

2018 Clinical Trials

106. Immune privilege disruption in folliculotropic mycosis fungoides: investigation of major histocompatibility complex antigen expression. (Abstract)

Immune privilege disruption in folliculotropic mycosis fungoides: investigation of major histocompatibility complex antigen expression. Folliculotropic mycosis fungoides (FMF) is a cutaneous T-cell lymphoma mainly affecting the hair follicle, which seems to represent a place of immune privilege phenomenon.To explore a possible role of immune privilege (IP) in FMF analyzing the major histocompatibility complex (MHC) expression.Immunohistochemistry for HLA-G and MHC-II was performed to formalin (...) -fixed paraffin-embedded cutaneous skin biopsies of FMF patients (n = 43), conventional mycosis fungoides (CMF; n = 13), alopecia areata (AA; n = 13), and normal scalp skin (NS; n = 12).HLA-G expression was lower in FMF (34%: 14/41) and CMF (18%: 2/11) groups compared to alopecia areata (92%:11/12) and normal scalp skin group (100%: 12/12). MHC-II expression in hair follicle was greater in the FMF group (18/42: 43%) compared to AA (0%) and NS (0%). HLA-G and MHC-II expression in cellular infiltrate

2018 International Journal of Dermatology

107. Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. Full Text available with Trip Pro

Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. Mycosis fungoides (MF) is a primary cutaneous T-cell lymphoma with unfavourable prognosis for patients with advanced stages of the disease. Refractory disease and advanced-stage disease require systemic therapy. We report on a rare case of an atypical predominantly CD8+ folliculotropic MF, a subtype of MF with poorer prognosis, in a 59-year-old

2018 British Journal of Dermatology

108. Erratum: Folliculotropic Mycosis Fungoides in 20 Korean Cases: Clinical and Histopathologic Features and Response to Ultraviolet A-1 and/or Photodynamic Therapy Full Text available with Trip Pro

Erratum: Folliculotropic Mycosis Fungoides in 20 Korean Cases: Clinical and Histopathologic Features and Response to Ultraviolet A-1 and/or Photodynamic Therapy [This corrects the article on p. 192 in vol. 30, PMID: 29606817.].

2018 Annals of dermatology

109. Identifying Prognostic Factors for Overall Survival in Mycosis Fungoides: A Systematic Review &amp Meta-Analysis

Identifying Prognostic Factors for Overall Survival in Mycosis Fungoides: A Systematic Review & Meta-Analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2020 PROSPERO

110. Mycosis fungoides in children and adolescents: a systematic review

Mycosis fungoides in children and adolescents: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2020 PROSPERO

111. Phototherapy for early-stage mycosis fungoides

Phototherapy for early-stage mycosis fungoides Phototherapy for early-stage mycosis fungoides Phototherapy for early-stage mycosis fungoides Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Phototherapy for early-stage mycosis fungoides. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication Dates. 2012 Authors' conclusions Cutaneous T-cell lymphomas (...) (CTCL) are a heterogeneous group of non-Hodgkin's lymphomas characterized by their initial manifestation in the skin. Mycosis fungoides (MF), which evolves from scaly skin patches and plaques, is the most common form of CTCL affecting approximately 65% of cases. The incidence of MF in the United States has been estimated at 6 cases per 1 million individuals with a male predominance. MF is broadly divided into early- and advanced-stage disease and classified into four clinical stages (I-IV). Skin

2012 Health Technology Assessment (HTA) Database.

112. A Case of Papular Mycosis Fungoides: A New Clinical Variant of Early Mycosis Fungoides Full Text available with Trip Pro

A Case of Papular Mycosis Fungoides: A New Clinical Variant of Early Mycosis Fungoides 27274640 2016 06 09 2018 11 13 1013-9087 28 3 2016 Jun Annals of dermatology Ann Dermatol A Case of Papular Mycosis Fungoides: A New Clinical Variant of Early Mycosis Fungoides. 383-4 10.5021/ad.2016.28.3.383 Kim Soo Jin SJ Department of Dermatology, Inje University Ilsan Paik Hospital, Goyang, Korea. Schaffer András A Dermatopathology Center, Washington University School in St. Louis, St. Louis, MO, USA. Lee

2016 Annals of dermatology

113. Recommendations for treatment in Folliculotropic Mycosis Fungoides: Report of the Dutch Cutaneous Lymphoma Group. (Abstract)

Recommendations for treatment in Folliculotropic Mycosis Fungoides: Report of the Dutch Cutaneous Lymphoma Group. Folliculotropic mycosis fungoides (FMF) is an aggressive variant of mycosis fungoides (MF) and generally less responsive to standard skin-directed therapies (SDTs). Recent studies distinguished indolent (early-stage FMF) and more aggressive (advanced-stage FMF) subgroups. The optimal treatment for both subgroups remains to be defined.To evaluate initial treatment results in patients

2017 British Journal of Dermatology

114. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. Full Text available with Trip Pro

Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached.To determine whether dose escalation

2017 JAMA dermatology (Chicago, Ill.)

115. Expression of Mucin 1 in Mycosis Fungoides Tumour Cells: A Case Report. Full Text available with Trip Pro

Expression of Mucin 1 in Mycosis Fungoides Tumour Cells: A Case Report. 28218332 2018 03 16 2018 03 16 1651-2057 97 6 2017 06 09 Acta dermato-venereologica Acta Derm. Venereol. Expression of Mucin 1 in Mycosis Fungoides Tumour Cells: A Case Report. 747-748 10.2340/00015555-2638 Shirai Takushi T Department of Dermatology, Shinshu University School of Medicine,, 3908621 Matsumoto, Japan. Kiniwa Yukiko Y Asaka Shiho S Shimojo Yasuyo Y Kamijo Fuminao F Okuyama Ryuhei R eng Case Reports Journal (...) Article Sweden Acta Derm Venereol 0370310 0001-5555 0 MUC1 protein, human 0 Mucin-1 IM Female Humans Immunohistochemistry Middle Aged Mucin-1 analysis Mycosis Fungoides chemistry Skin Neoplasms chemistry 2017 2 22 6 0 2018 3 17 6 0 2017 2 21 6 0 ppublish 28218332 10.2340/00015555-2638

2017 Acta Dermato-Venereologica

116. High Expression of Fas/CD95 on CD4+ Circulating T-cells: An Exclusion Criterion in the Diagnosis of Mycosis Fungoides? Full Text available with Trip Pro

High Expression of Fas/CD95 on CD4+ Circulating T-cells: An Exclusion Criterion in the Diagnosis of Mycosis Fungoides? The aim of this 10-year monocentric prospective study was to determine a cut-off value of Fas/CD95 expression by peripheral blood CD4+ T lymphocytes in discriminating patients with mycosis fungoides from controls with cutaneous benign lymphocytic conditions. CD95 expression in peripheral blood CD4+ T lymphocytes was measured using flow cytometry in 330 patients referred (...) for diagnosis: 104 with mycosis fungoides and 226 with eczema, psoriasis, drug reaction, etc. The sensitivity and specificity of different thresholds of CD95 expression were calculated regarding the final diagnosis of patients with mycosis fungoides or controls. CD95 expression higher than 30% reached a specificity of 91% in ruling out a diagnosis of mycosis fungoides, although overall CD95 expression was not significantly different from that of controls (p = 0.309) and sensitivity was very low (5%). Thus

2017 Acta Dermato-Venereologica

117. Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides

Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03454945 Recruitment Status : Recruiting First Posted : March 6, 2018 Last Update Posted : August

2017 Clinical Trials

118. Frequency and Risk Factors for Secondary Malignancies in Patients with Mycosis Fungoides Full Text available with Trip Pro

Frequency and Risk Factors for Secondary Malignancies in Patients with Mycosis Fungoides 28832009 2018 10 05 2018 11 13 1308-5263 34 4 2017 12 01 Turkish journal of haematology : official journal of Turkish Society of Haematology Turk J Haematol Frequency and Risk Factors for Secondary Malignancies in Patients with Mycosis Fungoides. 378-379 10.4274/tjh.2017.0234 Cengiz Fatma Pelin FP Bezmialem Vakıf University Faculty of Medicine, Department of Dermatovenereology, İstanbul, Turkey. Emiroğlu (...) Nazan N Bezmialem Vakıf University Faculty of Medicine, Department of Dermatovenereology, İstanbul, Turkey. Onsun Nahide N Bezmialem Vakıf University Faculty of Medicine, Department of Dermatovenereology, İstanbul, Turkey. eng Letter Mikozis Fungoidesli Hastalarda Sekonder Malignite Sıklığı ve Risk Faktörleri. 2017 08 23 Turkey Turk J Haematol 9606065 1300-7777 IM Adolescent Adult Aged Child Confidence Intervals Female Humans Male Middle Aged Mycosis Fungoides epidemiology Neoplasms, Second Primary

2017 Turkish Journal of Hematology

119. Case report: photo‐onycholysis after PUVA treatment for hypopigmented mycosis fungoides with response to topical steroid Full Text available with Trip Pro

Case report: photo‐onycholysis after PUVA treatment for hypopigmented mycosis fungoides with response to topical steroid Melanin in the nail bed in patients with skin type VI has been suggested to afford some protection against photo-onycholysis. We report a case of a 16-year-old male patient with skin type VI with onycholysis following PUVA treatment for hypopigmented mycosis fungoides. Symptoms resolved with the application of topical steroid.

2017 Clinical Case Reports

120. Hypopigmented Mycosis Fungoides Treated with 308 nm Excimer Laser Full Text available with Trip Pro

Hypopigmented Mycosis Fungoides Treated with 308 nm Excimer Laser 29386841 2018 11 13 1013-9087 30 1 2018 Feb Annals of dermatology Ann Dermatol Hypopigmented Mycosis Fungoides Treated with 308 nm Excimer Laser. 93-95 10.5021/ad.2018.30.1.93 Yang Min-Young MY Department of Dermatology, Pusan National University School of Medicine, Busan, Korea. Jin Hyunju H Department of Dermatology, Pusan National University School of Medicine, Busan, Korea. You Hyang-Suk HS Department of Dermatology, Pusan

2017 Annals of dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>